BR0117063A - Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores - Google Patents

Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores

Info

Publication number
BR0117063A
BR0117063A BR0117063-5A BR0117063A BR0117063A BR 0117063 A BR0117063 A BR 0117063A BR 0117063 A BR0117063 A BR 0117063A BR 0117063 A BR0117063 A BR 0117063A
Authority
BR
Brazil
Prior art keywords
cyclopamine
tumors
cell carcinoma
basal cell
tumor
Prior art date
Application number
BR0117063-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Sinan Tas
Oktay Avci
Original Assignee
Sinan Tas
Oktay Avci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0117063(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinan Tas, Oktay Avci filed Critical Sinan Tas
Publication of BR0117063A publication Critical patent/BR0117063A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
BR0117063-5A 2001-07-02 2001-07-02 Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores BR0117063A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (1)

Publication Number Publication Date
BR0117063A true BR0117063A (pt) 2004-07-27

Family

ID=21619326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0117063-5A BR0117063A (pt) 2001-07-02 2001-07-02 Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores

Country Status (14)

Country Link
EP (4) EP2862570A1 (OSRAM)
JP (3) JP2004536045A (OSRAM)
KR (1) KR20090125833A (OSRAM)
CN (2) CN1525859B (OSRAM)
AT (2) ATE305300T1 (OSRAM)
AU (1) AU2001272892B8 (OSRAM)
BR (1) BR0117063A (OSRAM)
CA (1) CA2452151C (OSRAM)
DE (2) DE60113733T2 (OSRAM)
DK (2) DK1401438T3 (OSRAM)
ES (3) ES2534400T3 (OSRAM)
PT (1) PT1411938E (OSRAM)
RU (1) RU2312661C2 (OSRAM)
WO (2) WO2002078703A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
EP2511298B1 (en) 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Compositions and Methods for Treating Cancer based on human FZD receptors
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2008070357A2 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008109184A1 (en) * 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
JP2010520310A (ja) * 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド シクロパミンラクタム類似体及びその使用方法
CN104059124A (zh) 2007-12-27 2014-09-24 无限药品股份有限公司 立体选择性还原的方法
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011123785A2 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015096654A1 (zh) * 2013-12-26 2015-07-02 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
HRP20251395T1 (hr) 2015-06-04 2026-02-13 Sol-Gel Technologies Ltd. Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
CN117940170A (zh) 2021-09-13 2024-04-26 辛南·塔斯 有效干预人类衰老和衰老疾病及其效果
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
CA2326654C (en) * 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
RU2232758C2 (ru) * 1998-09-23 2004-07-20 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
ES2233383T3 (es) * 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
CA2386190C (en) * 1999-10-13 2009-04-14 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
AU1935801A (en) * 1999-11-30 2001-06-12 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Also Published As

Publication number Publication date
CA2452151C (en) 2012-01-03
EP1401438B1 (en) 2005-09-28
EP1401438A1 (en) 2004-03-31
PT1411938E (pt) 2005-11-30
DE60204966T2 (de) 2006-05-18
WO2002078703A1 (en) 2002-10-10
CN1525859B (zh) 2010-05-05
JP2014028834A (ja) 2014-02-13
DK1411938T3 (da) 2005-11-07
DE60113733T2 (de) 2006-06-29
WO2002078703A8 (en) 2003-06-12
DK1401438T3 (da) 2006-02-13
EP2216022A1 (en) 2010-08-11
ES2250434T3 (es) 2006-04-16
EP2862570A1 (en) 2015-04-22
AU2001272892B8 (en) 2006-05-04
ATE299022T1 (de) 2005-07-15
WO2002078704A1 (en) 2002-10-10
DE60204966D1 (de) 2005-08-11
EP1561464A2 (en) 2005-08-10
RU2312661C2 (ru) 2007-12-20
CN1230169C (zh) 2005-12-07
EP2216022B1 (en) 2015-01-07
CN1522146A (zh) 2004-08-18
EP1561464A3 (en) 2007-04-25
DE60113733D1 (de) 2006-02-09
ES2534400T3 (es) 2015-04-22
ATE305300T1 (de) 2005-10-15
CA2452151A1 (en) 2002-10-10
RU2004103074A (ru) 2005-05-10
KR20090125833A (ko) 2009-12-07
ES2246011T3 (es) 2006-02-01
JP2010132691A (ja) 2010-06-17
JP5424923B2 (ja) 2014-02-26
AU2001272892B2 (en) 2006-03-16
JP2004536045A (ja) 2004-12-02
CN1525859A (zh) 2004-09-01

Similar Documents

Publication Publication Date Title
DK1401438T3 (da) Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
NZ544472A (en) Compounds and therapeutical use thereof
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
PT1202722E (pt) Usos para o tratamento ou prevencao de disturbios do sono usando doses muito baixas de ciclobenzaprina
DE60138611D1 (de) Synergistische kombinationstherapie zur krebsbehandlung
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
BR0115162A (pt) Tratamentos antitumorais eficazes
ATE406155T1 (de) Triptolid-prodrugs zur krebstherapie
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
DE60141194D1 (de) Behandlung des metastasierenden Karzinoms der Niere
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
WO2000037065A3 (en) Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
UY29136A1 (es) Uso de epotilonas en el tratamiento de metastasis osea
ATE362480T1 (de) Phenanthridinderivate und phenanthridin enthaltende antitumorale arzneimittel
UA42301A (uk) Засіб "камілаль" для лікування і профілактики проктологічних захворювань
DK1385497T3 (da) Forebyggelse eller behandling af bryst-, prostata- og/eller halscancer med N,N-dimethylglycin

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SINAN TAS (TR)

Free format text: TRANSFERIDO DE: OKTAY AVCI

B25G Requested change of headquarter approved

Owner name: SINAN TAS (TR)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060181175/RJ DE 05/12/2006.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]